Clostridium difficile colitis – Diagnostics – Overview of Information and Clinical Research

Diagnosing Clostridioides difficile colitis requires careful attention to symptoms, recent medical history, and specialized laboratory tests that can identify the bacteria or its toxins in stool samples.

Introduction: Who Should Undergo Diagnostics

If you are experiencing diarrhea and have recently taken antibiotics, been hospitalized, or stayed in a nursing home, your doctor may suspect a Clostridioides difficile (C. diff) infection. This condition should be considered in any person who has watery diarrhea at least three times in 24 hours and has been exposed to antibiotics within the past three months. However, it is important to note that C. diff can also affect people who have not taken antibiotics or been in healthcare settings, so doctors now test for it in community-dwelling individuals as well.^[1]^[4]

Testing is especially important for people over 65 years old, those with weakened immune systems, individuals who have had previous C. diff infections, or anyone recently hospitalized. The diagnosis becomes urgent when symptoms include severe diarrhea occurring 10 to 15 times per day, belly cramping and pain, fever, rapid heart rate, or signs of dehydration such as loss of fluids and abnormal heartbeat.^[1]^[2]

It is crucial to seek medical attention if you develop diarrhea while taking antibiotics or shortly after finishing a course of treatment. Symptoms typically begin within 5 to 10 days after starting an antibiotic, though they can appear as soon as the first day or up to three months later. If you notice bloody diarrhea, severe abdominal pain, high fever, or other worrisome symptoms, you should contact your healthcare provider immediately or seek urgent care.^[1]^[7]

⚠️ Important

People who have regular, formed stools should not be tested for C. diff infection. Testing should only be done in individuals experiencing diarrhea who are not taking laxatives. Testing asymptomatic individuals is not recommended because some healthy people carry the bacteria without becoming sick.^[10]

Diagnostic Methods for Identifying the Disease

Diagnosing C. diff infection primarily relies on examining a stool sample to detect either the bacteria itself or the harmful substances called toxins that it produces. Your doctor will ask about your symptoms and medical history, including recent antibiotic use and any hospital stays. The presence of watery diarrhea combined with recent antibiotic exposure or hospitalization raises strong suspicion for C. diff infection.^[4]^[10]

Stool Testing

The most common way to confirm C. diff infection is through laboratory testing of your stool. When C. diff infection is suspected, your healthcare provider will request one or more tests on a fresh stool sample. These tests can identify the bacteria by looking for its DNA or can detect the toxins that C. diff produces, which are responsible for causing the inflammation and damage to your colon.^[5]^[10]

A two-step testing approach is often used in medical laboratories. The first step involves an enzyme immunoassay test that checks for a substance called glutamate dehydrogenase (an enzyme produced by C. diff bacteria) and toxins A and B. If these initial results are unclear or indeterminate, a second test called nucleic acid amplification testing is performed. This second test looks for the genetic material (DNA) of C. diff bacteria. For patients who are very likely to have C. diff based on their symptoms, doctors may go straight to nucleic acid amplification testing or use the two-step process.^[13]

The stool test detects toxins that C. diff releases when it grows out of control in your intestines. These toxins cause mucosal inflammation and damage to the cells lining your intestinal wall, which leads to the characteristic watery diarrhea and other symptoms. It is important to provide a fresh stool sample as directed by your healthcare provider to ensure accurate results.^[4]^[5]

Visual Examination of the Colon

In some cases, particularly when the diagnosis is uncertain or the infection appears severe, your doctor may recommend looking inside your colon directly. This is done using a thin, flexible tube with a small camera on the end, inserted through the anus. Two types of procedures may be used: flexible sigmoidoscopy, which examines the lower part of the colon, or colonoscopy, which looks at the entire large intestine.^[4]^[10]

During these procedures, doctors may observe characteristic signs of C. diff infection, such as pseudomembranes—yellowish-white plaques or patches of raw tissue that appear on the intestinal lining. These membranes are formed from dead cells, white blood cells, and other debris. They can range from 2 to 10 millimeters in diameter and are scattered over the colorectal mucosa. Seeing these pseudomembranes helps confirm the diagnosis and indicates a more severe form of the infection called pseudomembranous colitis.^[4]

Visual examination can also help identify other potential complications, such as areas of severe inflammation, bleeding, or tissue damage. However, it is important to note that not all C. diff infections produce visible pseudomembranes, and their absence does not rule out the infection.^[4]

Imaging Tests

When C. diff infection is severe or complications are suspected, your doctor may order imaging tests to look at the condition of your colon and surrounding organs. An X-ray of the abdomen or a computed tomography (CT) scan can reveal important signs of advanced disease. These imaging tests can show a thickened colon wall, an enlarged bowel, or even a hole (called a perforation) in the lining of the colon.^[10]

CT scanning is particularly useful for detecting toxic megacolon, a rare but life-threatening complication where the colon becomes extremely distended and swollen. This condition requires immediate medical attention and may need emergency surgery. Imaging can also reveal fluid accumulation or other signs of severe inflammation that would not be apparent from stool tests alone.^[4]^[10]

A barium enema, an older type of X-ray test where contrast material is used to outline the colon, may sometimes show a characteristic serrated appearance of the intestinal wall. This pattern results from trapped barium between swollen mucosal folds and the plaque-like pseudomembranes. However, CT scans have largely replaced barium studies in modern practice because they provide more detailed information.^[4]

Diagnostics for Clinical Trial Qualification

When patients with C. diff infection are being considered for enrollment in clinical trials, specific diagnostic criteria must be met to ensure that participants truly have the condition being studied. Clinical trials testing new treatments for C. diff typically require confirmed laboratory evidence of infection through stool testing, showing either the presence of C. diff toxins or a positive nucleic acid amplification test that detects the bacteria’s genetic material.^[4]

Clinical trial protocols often define the severity of infection based on measurable criteria. These may include the frequency of diarrhea episodes (usually three or more unformed stools within 24 hours), the patient’s white blood cell count (which increases during infection), and serum creatinine level (a blood test that measures kidney function). Elevated white blood cell counts and worsening kidney function indicate more severe disease.^[13]

For studies evaluating treatments for recurrent C. diff infections, researchers need to document that a patient has had previous episodes. This requires evidence of at least one prior infection confirmed by laboratory testing, followed by resolution of symptoms with treatment, and then return of symptoms with another positive test result. Some trials may require patients to have experienced two or more recurrences before they can participate.^[13]

Additionally, clinical trials often assess the overall health status of potential participants through physical examinations and measurement of vital signs such as blood pressure, heart rate, and body temperature. These baseline assessments help researchers determine disease severity and track changes during treatment. Blood tests to evaluate liver and kidney function, as well as overall nutritional status, may also be part of the screening process for trial enrollment.^[4]

Researchers may also use endoscopic examination (colonoscopy or sigmoidoscopy) as part of clinical trial qualification, especially in studies investigating severe disease or novel treatments. Visual confirmation of pseudomembranes or other characteristic findings can help stratify patients by disease severity and ensure that the study population is appropriate for the intervention being tested.^[4]

Prognosis and Survival Rate

Prognosis

The outlook for people with C. diff infection varies widely depending on the severity of the disease, the patient’s overall health, and how quickly treatment begins. Most people with mild to moderate infection recover completely after taking the appropriate antibiotics. However, the infection has a tendency to return. About one in six people (approximately 16 to 17 percent) who recover from their first episode will develop another infection within 2 to 8 weeks. This recurrence can happen because the original infection was not fully cleared, or because the person came into contact with C. diff bacteria again during a vulnerable period.^[9]^[17]

For people who experience multiple recurrences, the chances of developing yet another episode increase significantly. The rate of disease recurrence is approximately 20 to 40 percent when using standard antibiotic treatments. Some individuals struggle with recurring infections for months or even years, which can significantly impact their quality of life and digestive health. Their gastrointestinal tract may take a long time to heal fully, and they may continue to experience digestive problems even after the infection clears.^[4]^[22]^[24]

Severe C. diff infections can lead to life-threatening complications. These include toxic megacolon (extreme swelling of the colon), perforation of the intestinal wall, severe dehydration, kidney failure, and sepsis (a dangerous whole-body response to infection). Patients with fulminant colitis—the most severe form—may require emergency surgery to remove part or all of the diseased colon. The risk of developing severe disease is higher in older adults (especially those over 65), people with weakened immune systems, those with other serious medical conditions, and individuals who have had previous C. diff infections.^[1]^[2]^[4]

Factors that influence prognosis include the patient’s age, the presence of other medical conditions, the strain of C. diff bacteria involved, and how quickly treatment is started. The emergence of a hypervirulent strain known as NAP1/027 or ribotype 027 has resulted in more severe infections and worse outcomes over the past two decades. This strain produces more toxins and is more resistant to standard treatments.^[6]^[12]

Survival Rate

C. diff infection causes approximately 15,000 deaths each year in the United States, out of about 500,000 total infections. This means that roughly 3 percent of people diagnosed with C. diff die as a direct result of the infection or its complications. However, the mortality rate is much higher in certain vulnerable groups.^[3]^[16]

Among people over 65 years old who acquire C. diff in healthcare settings such as hospitals or nursing homes, approximately one in eleven (about 9 percent) dies within one month of diagnosis. The risk of death increases significantly with age—older patients and those with multiple chronic health conditions face the greatest danger. In one large epidemic that occurred in Quebec, Canada, beginning in 2002, the cumulative one-year mortality rate attributable to C. diff infection reached 16.7 percent, meaning that nearly one in six infected patients died within a year.^[2]^[12]

Patients who develop fulminant colitis or toxic megacolon face particularly high mortality rates. Among those requiring emergency colectomy (surgical removal of the colon), the risk of death during or shortly after surgery is substantial. Blood markers can help predict which patients are at highest risk—significantly elevated serum lactate levels (5 millimoles per liter or higher) and very high white blood cell counts (50,000 cells per microliter or more) are associated with increased perioperative mortality.^[11]

It is important to emphasize that while these statistics reflect serious risks, many people recover fully from C. diff infection with appropriate treatment. Early recognition of symptoms, prompt diagnosis, and proper antibiotic therapy greatly improve survival chances. For those with recurrent infections, newer treatments such as fecal microbiota transplantation have shown promising results and may reduce the risk of future episodes.^[10]^[13]

#1 Clinical Trials Search in Europe